498 ES015, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response

• Rui Gao,
• Jing Gao,
• Chunnian Wang,
• Dawei Sun,
• Hongtao Lu,
• Wenqiang Lu,
• Quan Qiu,
• Jingfeng Yu,
• Zeyu Liu,
• Hongping Zhou

Affiliations

Rui Gao

1 Department of Cancer Prevention, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Guangzhou, People`s Republic of China

Jing Gao

Department of Oncology, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Cancer Institute, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen, China

Chunnian Wang

4Ningbo Clinical and Pathological Diagnosis Center, China

Dawei Sun

Elpiscience Biopharma, Ltd., Shanghai, China

Hongtao Lu

Elpiscience Biopharma, Ltd., Shanghai, China

Wenqiang Lu

Elpiscience Biopharma, Shanghai, China

Quan Qiu

Elpiscience Biopharma, Shanghai, China

Jingfeng Yu

Elpiscience Biopharma, Shanghai, China

Zeyu Liu

Elpiscience Biopharma, Ltd., Shanghai, China

Hongping Zhou

Elpiscience Biopharma, Ltd., Shanghai, China